Quickmic
Rapid antimicrobial susceptibility testing platform for clinical microbiology labs.
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in June 2025, Quickmic operates with 1–10 employees. The company is currently in the Pre-Funding stage.
Business overview
Quickmic (GradientenTech) is developing a rapid antimicrobial susceptibility testing (AST) solution for clinical microbiology laboratories. Its platform aims to accelerate the identification of effective antibiotics against bacterial infections, enabling earlier targeted therapy decisions and enhancing antibiotic stewardship. The company targets hospital and reference laboratories that require faster turnaround times and standardized workflows.
Log in to access full profile ›Company Intelligence Q&A
- What is Quickmic's primary focus?
- Quickmic's primary focus is developing a rapid antimicrobial susceptibility testing (AST) solution for clinical microbiology labs, designed to quickly determine effective antibiotics for bacterial infections.
- When was Quickmic founded?
- Quickmic was founded in June 2025.
- What problem does Quickmic aim to solve?
- Quickmic aims to solve the problem of slow traditional antimicrobial susceptibility testing, enabling faster results for targeted therapy decisions and improved antibiotic stewardship.
- Which markets does Quickmic target?
- Quickmic targets hospital and reference laboratories that require faster turnaround times and standardized workflows for antimicrobial susceptibility testing.